` EPRX (Eupraxia Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

EPRX
vs
S&P 500

Over the past 12 months, EPRX has significantly outperformed S&P 500, delivering a return of +162% compared to the S&P 500's +14% growth.

Back to EPRX Analysis

Stocks Performance
EPRX vs S&P 500

Loading
EPRX
S&P 500
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EPRX vs S&P 500

Loading
EPRX
S&P 500
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
EPRX vs S&P 500

Loading
EPRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Eupraxia Pharmaceuticals Inc vs Peers

S&P 500
EPRX
RYI
AVGR
BROG
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Eupraxia Pharmaceuticals Inc
Glance View

Market Cap
301.9m USD
Industry
Biotechnology

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

EPRX Intrinsic Value
Not Available
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.